On Oct 31, major Wall Street analysts update their ratings for $Biomarin Pharmaceutical (BMRN.US)$, with price targets ranging from $78 to $122.
Morgan Stanley analyst Vikram Purohit maintains with a buy rating, and maintains the target price at $112.
J.P. Morgan analyst Jessica Fye maintains with a buy rating, and adjusts the target price from $120 to $109.
BofA Securities analyst Jason Zemansky maintains with a buy rating.
Citi analyst David Lebowitz maintains with a hold rating, and adjusts the target price from $93 to $81.
Barclays analyst Gena Wang maintains with a buy rating, and maintains the target price at $86.
Furthermore, according to the comprehensive report, the opinions of $Biomarin Pharmaceutical (BMRN.US)$'s main analysts recently are as follows:
BioMarin experienced a strong quarter, with a slight increase in both top and bottom line forecasts. Analysts believe that the value of the company's enzyme replacement therapy business is at least equal to the current share price. Furthermore, the anticipation that BMN333, scheduled to enter clinical trials in early 2025, may notably contribute to the company's value by maintaining its position in achondroplasia and potentially expanding to additional indications where Voxzogo is undergoing studies.
BioMarin's third-quarter financial results surpassed expectations both in terms of revenue and earnings, with a slight increase in the forecast for fiscal 2024 across all key indicators. Despite Voxzogo's performance falling short of projections, the shortfall was compensated by stronger-than-anticipated outcomes from a number of products within the company's enzyme replacement therapy segment.
The firm recognizes an appealing entry point for BioMarin's shares, highlighting the company's solid foundational business and the prospects for significant operating margin growth in the coming years.
BioMarin's third-quarter 2024 financials and pipeline updates were generally aligned with market forecasts. The slight increase in the company's 2024 guidance is positive; however, the perceived deceleration in Voxzogo's growth, which is seen as a pivotal element for BioMarin's success, may not meet investor expectations.
Here are the latest investment ratings and price targets for $Biomarin Pharmaceutical (BMRN.US)$ from 16 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美東時間10月31日，多家華爾街大行更新了$拜瑪林製藥 (BMRN.US)$的評級，目標價介於78美元至122美元。
摩根士丹利分析師Vikram Purohit維持買入評級，維持目標價112美元。
摩根大通分析師Jessica Fye維持買入評級，並將目標價從120美元下調至109美元。
美銀證券分析師Jason Zemansky維持買入評級。
花旗分析師David Lebowitz維持持有評級，並將目標價從93美元下調至81美元。
巴克萊銀行分析師Gena Wang維持買入評級，維持目標價86美元。
此外，綜合報道，$拜瑪林製藥 (BMRN.US)$近期主要分析師觀點如下：
BioMarin在第四季度取得了強勁表現，預測的營收和利潤略微增加。分析師認爲，公司酶替代療法業務的價值至少等於當前股價。此外，預計BMN333計劃於2025年初進入臨床試驗，可能通過保持在骨發育不全領域的地位並潛在擴展到Voxzogo正在進行研究的其他適應症領域，顯著提高公司價值。
BioMarin第三季度的財務業績在營收和盈利方面均超出預期，2024財年各項關鍵指標的預測略微增加。儘管Voxzogo的表現未達預期，但公司酶替代療法部門內一些產品的業績強於預期，部分彌補了這一不足。
公司認爲BioMarin股票具有吸引人的入市時機，突出了公司堅實的基礎業務和未來幾年中顯著營業利潤率增長的前景。
BioMarin 2024年第三季度的財務數據和產品管線更新基本符合市場預期。公司2024年業績指引的輕微增加是積極的；然而，Voxzogo增長速度的認知減緩被看作BioMarin成功的關鍵因素，可能無法滿足投資者的預期。
以下爲今日16位分析師對$拜瑪林製藥 (BMRN.US)$的最新投資評級及目標價：
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
